AdvertisementSTOCKHOLM, May 30, 2024 /PRNewswire/ — Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at Redeye Growth Day, today May 30, 2024. CEO Jens Lindberg will present updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and the development plans moving forward at 09.40 CET. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. This information was brought to you by Cision http://news.cision.comhttps://news.cision.com/medivir/r/medivir-to-present-at-redeye-growth-day,c3991569The following files are available for download:https://mb.cision.com/Main/652/3991569/2833364.pdf Press release (PDF)View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-redeye-growth-day-302159105.htmlSOURCE MedivirDisclaimer: The above press release comes to you under an arrangement with PR Newswire.

Source: The Bubble May 30, 2024 19:50 UTC